Glp-1 Therapy And Extracorporeal Circulation

Overview of Glp-1 Therapy And Extracorporeal Circulation

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy , and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...

The clinical trials investigating the impact of GLP -1RA on cardiovascular health have shown that the incidence of MACE does not differ between the GLP -1R agonist and placebo groups until 12-18 months after initiation of therapy , which aligns with the potential anti-atherogenic effect of GLP -1RA (Sattar et al. 2021).

Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Therapy And Extracorporeal Circulation.

The function of GIP and GLP-1 to reduce glycemia through glucose-dependent potentiation of insulin secretion provided the initial rationale for exploring the feasibility of GLP -1R agonist ( GLP -1RA)-based peptide therapies for the management of type 2 diabetes mellitus (T2DM). GLP -1RAs are a class of drugs resistant to degradation by the ubiquitous protease dipeptidyl peptidase-4 (DPP4), known ...